相关实验视频
Updated: Jan 9, 2026
08:03
In Vitro Model of Coronary Angiogenesis
Published on: March 10, 2020
8.4K
内皮LRRC8A通过促进冠状动脉血管生成,减轻压力过载引起的心脏缩
Lingjun Jie1,2,3, Baolong Feng4, Yufan Zhou4
1Institute of Cardiovascular Diseases, Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China. jie.lj@xmu.edu.cn.
Angiogenesis
|December 7, 2025
概括
富含白的内皮重复含有8A (LRRC8A) 对于预防心脏缩和心力衰竭至关重要. 在内皮细胞中恢复LRRC8A促进血管生成,并在压力过载后改善心脏功能.
科学领域:
- 心血管生物学 心血管生物学
- 内皮细胞生物学 内皮细胞生物学
- 分子心脏病学分子心脏病学
背景情况:
- 压力过载导致心脏缩和心力衰竭,其中内皮功能障碍是关键驱动因素.
- 富含白的重复含有8A (LRRC8A) 调节血管内皮平衡,但其在心脏缩中的作用尚不清楚.
研究的目的:
- 研究内皮LRRC8A在压力过载引起的病态心脏缩中的作用和机制.
主要方法:
- 分析了人类和小鼠高性心脏和心脏内皮细胞 (CEC) 中的LRRC8A表达.
- 利用内皮LRRC8A淘汰赛小鼠并进行横向大动脉收缩 (TAC) 手术.
- 在CEC上进行单细胞RNA测序 (scRNA-seq),体内血管生成试验和体内内皮细胞功能试验.
- 研究了LRRC8A,VEGF-VEGFR2信号传递和VEGFR2内细胞分裂之间的机制联系.
- 在小鼠模型中使用了AAV9-ICAM2-LRRC8A基因疗法.
主要成果:
- 在高性心脏和CEC中,LRRC8A表达的下调.
- 内皮LRRC8A缺陷加剧了TAC诱导的心脏缩和功能障碍.
- 缺乏LRRC8A会影响血管生成,CEC迁移和增殖,并减少毛细血管密度.
- LRRC8A积极调节了VEGF-VEGFR2轴,与VEGFR2相互作用,并促进了其内细胞分裂.
- 恢复LRRC8A的基因疗法改善了冠状动脉血管生成,改善了心脏缩和功能障碍.
结论:
- 内皮LRRC8A是冠状动脉血管生成的关键调节者,用于压力过载引起的心脏缩.
- LRRC8A代表了治疗心脏缩和心力衰竭的潜在治疗标.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
01:29Heart Failure II: Pathophysiology
685
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
685
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K